{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:52:08Z","timestamp":1788382328753,"version":"build-2803163510"},"reference-count":225,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine &amp; Growth Factor Reviews"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.cytogfr.2021.03.006","type":"journal-article","created":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T06:52:53Z","timestamp":1618469573000},"page":"28-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1\/2 inhibitors in combination with interferon"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3936-8032","authenticated-orcid":false,"given":"H.C.","family":"Hasselbalch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0097-7826","authenticated-orcid":false,"given":"V.","family":"Skov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Kj\u00e6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ellervik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.D.","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.H.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cytogfr.2021.03.006_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China. A descriptive study","author":"Chen","year":"2020","journal-title":"Lancet"},{"issue":"395","key":"10.1016\/j.cytogfr.2021.03.006_bib0010","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.cytogfr.2021.03.006_bib0015","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1056\/NEJMoa2004500","article-title":"Covid-19 in critically ill patients in the Seattle region - case series","volume":"382","author":"Bhatraju","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.cytogfr.2021.03.006_bib0020","first-page":"1","article-title":"Virus-associated hemophagocytic syndrome as a major contributor to death in patients with 2009 influenza A (H1N1) infection","author":"Beutel","year":"2011","journal-title":"Crit. Care"},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(20)30132-8","article-title":"COVID-19: combining antiviral and anti-inflammatory treatments","author":"Stebbing","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0030","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCOV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet"},{"issue":"March (395)","key":"10.1016\/j.cytogfr.2021.03.006_bib0035","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"28","author":"Mehta","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.cytogfr.2021.03.006_bib0040","doi-asserted-by":"crossref","first-page":"337","DOI":"10.55563\/clinexprheumatol\/xcdary","article-title":"COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?","volume":"38","author":"Sarzi-Puttini","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0045","article-title":"SARS-CoV-2: a storm is raging [published online ahead of print, 2020 Mar 27]","author":"Pedersen","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0050","first-page":"M20","article-title":"Autopsy Findings and Venous Thromboembolism in Patients With COVID-19 [published online ahead of print, 2020 May 6]","author":"Wichmann","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0055","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.thromres.2020.04.013","article-title":"Incidence of thrombotic complications in critically ill ICU patients with COVID-19","volume":"191","author":"Klok","year":"2020","journal-title":"Thromb. Res."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0060","article-title":"Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19 [published online ahead of print, 2020 May 21]","author":"Ackermann","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.cytogfr.2021.03.006_bib0065","doi-asserted-by":"crossref","first-page":"E1417","DOI":"10.3390\/jcm9051417","article-title":"Hypertension, thrombosis, kidney failure, and diabetes: is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence","volume":"9","author":"Sardu","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0070","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.thromres.2020.04.042","article-title":"COVID-19 associated pulmonary thrombosis","volume":"191","author":"van Nieuwkoop","year":"2020","journal-title":"Thromb. Res."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0075","article-title":"COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up [published online ahead of print, 2020 Apr 15]","author":"Bikdeli","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"23","key":"10.1016\/j.cytogfr.2021.03.006_bib0080","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood.2020006000","article-title":"COVID-19 and its implications for thrombosis and anticoagulation","volume":"135","author":"Connors","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0085","article-title":"Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases [published online ahead of print, 2020 Apr 15]","author":"Magro","year":"2020","journal-title":"Transl. Res."},{"issue":"22","key":"10.1016\/j.cytogfr.2021.03.006_bib0090","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1161\/CIRCULATIONAHA.120.047419","article-title":"Will complement inhibition be the new target in treating Covid-19-related systemic thrombosis?","volume":"141","author":"Campbell","year":"2020","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.cytogfr.2021.03.006_bib0095","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.1016\/S2352-3026(20)30145-9","article-title":"Coagulation abnormalities and thrombosis in patients with COVID-19","volume":"7","author":"Levi","year":"2020","journal-title":"Lancet Haematol."},{"issue":"5","key":"10.1016\/j.cytogfr.2021.03.006_bib0100","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/bjh.16727","article-title":"Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action","volume":"189","author":"Kollias","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0105","article-title":"Hematological findings and complications of COVID-19 [published online ahead of print, 2020 Apr 13]","author":"Terpos","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/j.cytogfr.2021.03.006_bib0110","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s12975-020-00818-9","article-title":"COVID-19-Related stroke","volume":"11","author":"Hess","year":"2020","journal-title":"Transl. Stroke Res."},{"issue":"6","key":"10.1016\/j.cytogfr.2021.03.006_bib0115","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1055\/s-0040-1710018","article-title":"COVID-19-Related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure","volume":"120","author":"Spiezia","year":"2020","journal-title":"Thromb. Haemost."},{"issue":"192","key":"10.1016\/j.cytogfr.2021.03.006_sbref0120a","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.thromres.2020.05.025","article-title":"Severe arterial thrombosis associated with Covid-19 infection [published online ahead of print, 2020 May 16]","author":"Kashi","year":"2020","journal-title":"Thromb. Res."},{"key":"10.1016\/j.cytogfr.2021.03.006_sbref0120b","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood.2020006000","article-title":"COVID-19 and its implications for thrombosis and anticoagulation","volume":"135","author":"Connors","year":"2020","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.cytogfr.2021.03.006_bib0125","doi-asserted-by":"crossref","first-page":"313","DOI":"10.4014\/jmb.2003.03011","article-title":"Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19)","volume":"30","author":"Ahn","year":"2020","journal-title":"J. Microbiol. Biotechnol."},{"issue":"7","key":"10.1016\/j.cytogfr.2021.03.006_bib0130","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.3390\/ijms21072657","article-title":"A review of SARS-CoV-2 and the ongoing clinical trials","volume":"21","author":"Tu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0135","article-title":"Compassionate use of remdesivir for patients with severe Covid-19 [published online ahead of print, 2020 Apr 10]","author":"Grein","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0140","article-title":"Remdesivir for 5 or 10 days in patients with severe Covid-19 [published online ahead of print, 2020 May 27]","author":"Goldman","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10236","key":"10.1016\/j.cytogfr.2021.03.006_bib0145","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial [published correction appears in Lancet. 2020 May 30;395(10238):1694]","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0150","article-title":"Remdesivir for the treatment of Covid-19 - preliminary report [published online ahead of print, 2020 May 22]","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0155","article-title":"Remdesivir for the treatment of Covid-19 - final report [published online ahead of print, 2020 Oct 8]","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmni.2020.100745","article-title":"Critical reappraisal of remdesivir investigational trials in COVID-19","volume":"38","author":"Brouqui","year":"2020","journal-title":"New Microbes New Infect."},{"issue":"October (371)","key":"10.1016\/j.cytogfr.2021.03.006_bib0165","article-title":"Covid-19: remdesivir has little or no impact on survival, WHO trial shows","volume":"19","author":"Dyer","year":"2020","journal-title":"BMJ"},{"issue":"September (9)","key":"10.1016\/j.cytogfr.2021.03.006_bib0170","article-title":"Interventions for treatment of COVID-19: a living systematic review with meta-analyses and trial sequential analyses (the LIVING Project)","volume":"17","author":"Juul","year":"2020","journal-title":"PLoS Med."},{"issue":"5167","key":"10.1016\/j.cytogfr.2021.03.006_bib0175","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1126\/science.8009221","article-title":"Functional role of type I and type II interferons in antiviral defense","volume":"24","author":"M\u00fcller","year":"1994","journal-title":"Science."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0180","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1128\/CMR.14.4.778-809.2001","article-title":"Antiviral actions of interferons","volume":"14","author":"Samuel","year":"2001","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2019.101300","article-title":"Global virus outbreaks: interferons as 1st responders","volume":"43","author":"Wang","year":"2019","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0190","first-page":"1","article-title":"Compounds with therapeutic potential against novel respiratory 2019 coronavirus","author":"Martinez","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"August (8)","key":"10.1016\/j.cytogfr.2021.03.006_bib0195","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.cmi.2020.05.019","article-title":"Review of trials currently testing treatment and prevention of COVID-19","volume":"26","author":"Fragkou","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0200","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5582\/ddt.2020.01012","article-title":"Discovering drugs to treat coronavirus disease 2019 (COVID-19)","volume":"14","author":"Dong","year":"2020","journal-title":"Drug Discov. Ther."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0205","article-title":"SARS-CoV-2 sensitive to type I interferon pretreatment","author":"Lokugamage","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0210","article-title":"COVID-19: pathogenesis, cytokine storm and therapeutic potential of interferons [published online ahead of print, 2020 May 7]","author":"Nile","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"issue":"178","key":"10.1016\/j.cytogfr.2021.03.006_bib0215","article-title":"Type 1 interferons as a potential treatment against COVID-19 [published online ahead of print, 2020 Apr 7]","author":"Sallard","year":"2020","journal-title":"Antiviral Res."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0220","article-title":"COVID-19: lambda interferon against viral load and hyperinflammation [published online ahead of print, 2020 Apr 25]","author":"Andreakos","year":"2020","journal-title":"EMBO Mol. Med."},{"issue":"10238","key":"10.1016\/j.cytogfr.2021.03.006_bib0225","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(20)31101-6","article-title":"Interferon beta-1b for COVID-19","volume":"395","author":"Shalhoub","year":"2020","journal-title":"Lancet"},{"issue":"10238","key":"10.1016\/j.cytogfr.2021.03.006_bib0230","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.idcr.2020.e00837","article-title":"Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a","volume":"21","author":"El-Lababidi","year":"2020","journal-title":"IDCases"},{"issue":"3","key":"10.1016\/j.cytogfr.2021.03.006_bib0240","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.chom.2020.07.005","article-title":"Retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients","volume":"28","author":"Wang","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0245","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.3389\/fimmu.2020.01061","article-title":"Interferon-alpha2b treatment for COVID-19","volume":"11","author":"Zhou","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0250","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijid.2020.07.053","article-title":"SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: a randomized, open-label, parallel-group trial","volume":"99","author":"Zheng","year":"2020","journal-title":"Int. J. Infect. Dis."},{"issue":"9","key":"10.1016\/j.cytogfr.2021.03.006_bib0255","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01061-20","article-title":"A randomized clinical trial of the efficacy and safety of interferon beta-1a in treatment of severe COVID-19","volume":"64","author":"Davoudi-Monfared","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"November","key":"10.1016\/j.cytogfr.2021.03.006_bib0260","article-title":"Interferon \u03b2-1b in treatment of severe COVID-19: a randomized clinical trial","volume":"88","author":"Rahmani","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"9","key":"10.1016\/j.cytogfr.2021.03.006_bib0265","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1089\/jir.2020.0124","article-title":"Therapeutic effetiveness of interferon-alpha2b against COVID-19: the Cuban experience","volume":"40","author":"Pereda","year":"2020","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100547","article-title":"An open-label, randomized trial of the combination of IFN-kappa plus TFF2 with standard care in the treatment of patients with moderate COVID-19","volume":"27","author":"Fu","year":"2020","journal-title":"EClinicalMedicine."},{"issue":"June(11)","key":"10.1016\/j.cytogfr.2021.03.006_bib0275","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3389\/fphar.2020.00857","article-title":"Combination of ruxolitinib and eculizumab for treatment of severe SARS-CoV-2-Related acute respiratory distress syndrome: a controlled study","volume":"5","author":"Giudice","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"November","key":"10.1016\/j.cytogfr.2021.03.006_bib0280","article-title":"JAK-STAT pathway inhibition and their implications in COVID-19 therapy","volume":"27","author":"Satarker","year":"2020","journal-title":"Postgrad. Med."},{"issue":"August (8)","key":"10.1016\/j.cytogfr.2021.03.006_bib0285","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1038\/s41375-020-0907-9","article-title":"Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)","volume":"34","author":"Neubauer","year":"2020","journal-title":"Leukemia."},{"issue":"November (11)","key":"10.1016\/j.cytogfr.2021.03.006_bib0290","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.clml.2020.06.014","article-title":"Attenuated novel SARS coronavirus 2 infection in an allogeneic hematopoietic stem cell transplant patient on ruxolitinib","volume":"20","author":"Foss","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"November (1\u20134)","key":"10.1016\/j.cytogfr.2021.03.006_bib0295","article-title":"Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia","volume":"10","author":"D\u2019Alessio","year":"2020","journal-title":"Leukemia."},{"issue":"July (1)","key":"10.1016\/j.cytogfr.2021.03.006_bib0300","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaci.2020.05.019","article-title":"Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial","volume":"146","author":"Cao","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"7","key":"10.1016\/j.cytogfr.2021.03.006_bib0305","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1038\/s41375-020-0891-0","article-title":"The Janus kinase 1\/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation","volume":"34","author":"La Ros\u00e9e","year":"2020","journal-title":"Leukemia."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0310","first-page":"1","article-title":"Compassionate use of JAK1\/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study","author":"Vannucchi","year":"2020","journal-title":"Leukemia"},{"issue":"July","key":"10.1016\/j.cytogfr.2021.03.006_bib0315","first-page":"1","article-title":"JAK\/STAT pathway inhibition may Be a promising therapy for COVID-19-Related hyperinflammation in hematologic patients","volume":"29","author":"Rojas","year":"2020","journal-title":"Acta Haematol."},{"issue":"October(10)","key":"10.1016\/j.cytogfr.2021.03.006_bib0320","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1038\/s41375-020-01038-8","article-title":"The Janus kinase 1\/2 inhibitor ruxolitinib in COVID-19","volume":"34","author":"Gozzetti","year":"2020","journal-title":"Leukemia."},{"issue":"May","key":"10.1016\/j.cytogfr.2021.03.006_bib0325","article-title":"Weathering the COVID-19 storm: lessons from hematologic cytokine syndromes","volume":"15","author":"England","year":"2020","journal-title":"Blood Rev."},{"issue":"July (7)","key":"10.1016\/j.cytogfr.2021.03.006_bib0330","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1038\/s41375-020-0898-6","article-title":"Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation","volume":"34","author":"Heidel","year":"2020","journal-title":"Leukemia."},{"issue":"6","key":"10.1016\/j.cytogfr.2021.03.006_bib0335","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1159\/000508247","article-title":"JAK inhibition as a new treatment strategy for patients with COVID-19","volume":"181","author":"Seif","year":"2020","journal-title":"Int. Arch. Allergy Immunol."},{"issue":"June (11)","key":"10.1016\/j.cytogfr.2021.03.006_bib0340","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.3389\/fimmu.2020.01445","article-title":"Potential treatments for COVID-19 related cytokine storm - beyond corticosteroids","volume":"16","author":"Miao","year":"2020","journal-title":"Front. Immunol."},{"issue":"September","key":"10.1016\/j.cytogfr.2021.03.006_bib0345","article-title":"Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment","volume":"218","author":"Yeleswaram","year":"2020","journal-title":"Clin. Immunol."},{"issue":"7","key":"10.1016\/j.cytogfr.2021.03.006_bib0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102567","article-title":"Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions","volume":"19","author":"Jamilloux","year":"2020","journal-title":"Autoimmun. Rev."},{"issue":"October (1)","key":"10.1016\/j.cytogfr.2021.03.006_bib0355","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12985-020-01415-w","article-title":"Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents","volume":"17","author":"Khadke","year":"2020","journal-title":"Virol. J."},{"issue":"August (8)","key":"10.1016\/j.cytogfr.2021.03.006_bib0360","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.tips.2020.06.007","article-title":"Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19","volume":"41","author":"Luo","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"issue":"August (9)","key":"10.1016\/j.cytogfr.2021.03.006_bib0365","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11095-020-02851-7","article-title":"Repurposing of kinase inhibitors for treatment of COVID-19","volume":"37","author":"Weisberg","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0370","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.3389\/fonc.2019.01186","article-title":"Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib","volume":"9","author":"Elli","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0375","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs."},{"issue":"October","key":"10.1016\/j.cytogfr.2021.03.006_bib0380","article-title":"Immunobiology and immunotherapy of COVID-19: a clinically updated overview","volume":"6","author":"Esmaeilzadeh","year":"2020","journal-title":"J. Cell. Physiol."},{"issue":"August","key":"10.1016\/j.cytogfr.2021.03.006_bib0385","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cytogfr.2020.06.013","article-title":"The potential of JAK\/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19","volume":"54","author":"Goker Bagca","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"issue":"November","key":"10.1016\/j.cytogfr.2021.03.006_bib0390","article-title":"Immunotherapeutic approaches to curtail COVID-19","volume":"88","author":"Owji","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"July (1)","key":"10.1016\/j.cytogfr.2021.03.006_bib0395","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/JLB.3COVR0520-272R","article-title":"Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts","volume":"108","author":"Wang","year":"2020","journal-title":"J. Leukoc. Biol."},{"issue":"June (6)","key":"10.1016\/j.cytogfr.2021.03.006_bib0400","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","article-title":"The trinity of COVID-19: immunity, inflammation and intervention","volume":"20","author":"Tay","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"July","key":"10.1016\/j.cytogfr.2021.03.006_bib0405","article-title":"Therapeutic and vaccine strategies against SARS-CoV-2: past, present and future","author":"Rehman","year":"2020","journal-title":"Future Virol."},{"issue":"September (11)","key":"10.1016\/j.cytogfr.2021.03.006_bib0410","article-title":"Potential therapeutic options for COVID-19: current status, challenges, and future perspectives","volume":"15","author":"Sarkar","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"October","key":"10.1016\/j.cytogfr.2021.03.006_bib0415","first-page":"1","article-title":"Inflammation triggered by SARS-CoV-2 and ACE2 augment drives multiple organ failure of severe COVID-19: molecular mechanisms and implications","volume":"8","author":"Iwasaki","year":"2020","journal-title":"Inflammation."},{"issue":"September(3)","key":"10.1016\/j.cytogfr.2021.03.006_bib0420","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jaci.2020.07.001","article-title":"The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection","volume":"146","author":"Copaescu","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"August (4)","key":"10.1016\/j.cytogfr.2021.03.006_bib0425","first-page":"e198","article-title":"Ruxolitinib for tocilizumab-refractory severe COVID-19 infection","volume":"190","author":"Innes","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"August (4)","key":"10.1016\/j.cytogfr.2021.03.006_bib0430","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/bjh.16966","article-title":"Combined IL-6 and JAK\/STAT inhibition therapy in COVID-19-related sHLH, potential game changer","volume":"190","author":"Portsmore","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"August (11)","key":"10.1016\/j.cytogfr.2021.03.006_bib0435","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3389\/fphar.2020.01258","article-title":"Repurposing drugs, ongoing vaccine, and new therapeutic development initiatives against COVID-19","volume":"19","author":"Saha","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"November","key":"10.1016\/j.cytogfr.2021.03.006_bib0440","article-title":"A comprehensive review on potential therapeutics interventions for COVID-19","volume":"20","author":"Chugh","year":"2020","journal-title":"Eur. J. Pharmacol."},{"issue":"September (1)","key":"10.1016\/j.cytogfr.2021.03.006_bib0445","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/s12967-020-02520-8","article-title":"Pathophysiology and treatment strategies for COVID-19","volume":"18","author":"Kumar","year":"2020","journal-title":"J. Transl. Med."},{"issue":"August (8)","key":"10.1016\/j.cytogfr.2021.03.006_bib0450","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-020-0451-z","article-title":"COVID-19 revisiting inflammatory pathways of arthritis","volume":"16","author":"Schett","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"issue":"January(2)","key":"10.1016\/j.cytogfr.2021.03.006_bib0455","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.cell.2020.11.007","article-title":"Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques","volume":"184","author":"Hoang","year":"2021","journal-title":"Cell."},{"issue":"October","key":"10.1016\/j.cytogfr.2021.03.006_bib0460","article-title":"Modeling the viral dynamics of SARS-CoV-2 infection","volume":"328","author":"Wang","year":"2020","journal-title":"Math. Biosci."},{"issue":"5","key":"10.1016\/j.cytogfr.2021.03.006_bib0465","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","article-title":"Imbalanced host response to SARS-CoV-2 drives development of COVID-19","volume":"181","author":"Blanco-Melo","year":"2020","journal-title":"Cell."},{"issue":"July","key":"10.1016\/j.cytogfr.2021.03.006_bib0470","article-title":"Dexamethasone in hospitalized patients with Covid-19 - preliminary report","volume":"17","author":"RECOVERY Collaborative Group","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.cytogfr.2021.03.006_bib0475","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200652","article-title":"Targeting potential drivers of COVID-19: neutrophil extracellular traps","volume":"217","author":"Barnes","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0480","article-title":"The science underlying COVID-19: implications for the cardiovascular system [published online ahead of print, 2020 Apr15]","author":"Liu","year":"2020","journal-title":"Circulation."},{"issue":"June (13)","key":"10.1016\/j.cytogfr.2021.03.006_bib0485","doi-asserted-by":"crossref","first-page":"4662","DOI":"10.3390\/ijms21134662","article-title":"Putative roles for peptidylarginine deiminases in COVID-19","volume":"21","author":"Arisan","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0490","doi-asserted-by":"crossref","first-page":"19630","DOI":"10.1038\/s41598-020-76781-0","article-title":"The emerging role of neutrophil extracellular traps in severe acute respiratory syndrome coronavirus 2 (COVID-19)","volume":"10","author":"Arcanjo","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0495","first-page":"e138999","volume":"5","author":"Zuo","year":"2020"},{"issue":"12","key":"10.1016\/j.cytogfr.2021.03.006_bib0500","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201129","article-title":"SARS-CoV-2\u2013triggered neutrophil extracellular traps mediate COVID-19 pathology","volume":"217","author":"Veras","year":"2020","journal-title":"J. Exp. Med."},{"issue":"10","key":"10.1016\/j.cytogfr.2021.03.006_bib0505","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1182\/blood.2020007008","article-title":"Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome","volume":"136","author":"Middleton","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cytogfr.2021.03.006_bib0510","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.immuni.2011.02.006","article-title":"Type I interferon inhibits interleukin-1 production and inflammasome activation","volume":"34","author":"Guarda","year":"2011","journal-title":"Immunity"},{"issue":"Supplement1","key":"10.1016\/j.cytogfr.2021.03.006_bib0515","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1182\/blood-2019-131698","article-title":"Significantly upregulated thromboinflammatory genes are normoregulated or significantly downregulated during treatment with interferon-alpha2 in patients with Philadelphia-negative chronic myeloproliferative neoplasms","volume":"134","author":"Skov","year":"2019","journal-title":"Blood."},{"issue":"April(436)","key":"10.1016\/j.cytogfr.2021.03.006_bib0520","article-title":"Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms","volume":"10","author":"Wolach","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"May (5)","key":"10.1016\/j.cytogfr.2021.03.006_bib0525","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.cytogfr.2021.03.006_bib0530","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1182\/blood-2011-11-394775","article-title":"Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?","volume":"119","author":"Hasselbalch","year":"2012","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.cytogfr.2021.03.006_bib0535","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.leukres.2012.10.020","article-title":"Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia,polycythemia vera and myelofibrosis. A human inflammation model for cancer development?","volume":"37","author":"Hasselbalch","year":"2013","journal-title":"Leuk. Res."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0540","article-title":"MPNs as inflammatory diseases: the evidence, consequences","volume":"2015","author":"Hasselbalch","year":"2015","journal-title":"and Perspectives. Mediators Inflamm."},{"issue":"6","key":"10.1016\/j.cytogfr.2021.03.006_bib0545","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ccr3.281","article-title":"The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms","volume":"3","author":"Bj\u00f8rn","year":"2015","journal-title":"Clin. Case Rep."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0550","doi-asserted-by":"crossref","first-page":"e371","DOI":"10.1097\/HS9.0000000000000371","article-title":"Longitudinal cytokine profiling identifies GRO-a and EGF as potential biomarkers of disease progression in essential thrombocythemia","volume":"4","author":"\u00d8bro","year":"2020","journal-title":"HemaSphere."},{"issue":"June (3)","key":"10.1016\/j.cytogfr.2021.03.006_bib0555","doi-asserted-by":"crossref","first-page":"e407","DOI":"10.1097\/HS9.0000000000000407","article-title":"Cytokine profiling as a novel complementary tool to predict prognosis in MPNs?","volume":"4","author":"Hasselbalch","year":"2020","journal-title":"Hemasphere."},{"issue":"7","key":"10.1016\/j.cytogfr.2021.03.006_bib0560","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/0885066613517076","article-title":"Hemophagocytic syndrome and critical illness: new insights into diagnosis and management","volume":"30","author":"Tothova","year":"2015","journal-title":"J. Intensive Care Med."},{"issue":"10","key":"10.1016\/j.cytogfr.2021.03.006_bib0565","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s00134-010-1936-z","article-title":"Critical care management of patients with hemophagocytic lymphohistiocytosis","volume":"36","author":"Buyse","year":"2010","journal-title":"Intensive Care Med."},{"issue":"17","key":"10.1016\/j.cytogfr.2021.03.006_bib0570","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1182\/blood-2011-06-356261","article-title":"Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol","volume":"118","author":"Trottestam","year":"2011","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.cytogfr.2021.03.006_bib0575","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00432-020-03139-4","article-title":"Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registry","volume":"146","author":"Birndt","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0580","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1146\/annurev-pathol-020117-043625","article-title":"Hemophagocytic lymphohistiocytosis","volume":"13","author":"Al-Samkari","year":"2018","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0585","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fimmu.2019.00119","article-title":"The immunology of macrophage activation syndrome","volume":"10","author":"Crayne","year":"2019","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.cytogfr.2021.03.006_bib0590","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2003-10-3413","article-title":"An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder","volume":"104","author":"Jordan","year":"2004","journal-title":"Blood."},{"issue":"13","key":"10.1016\/j.cytogfr.2021.03.006_bib0595","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1182\/blood-2016-02-697151","article-title":"Alleviating the storm: ruxolitinib in HLH","volume":"127","author":"La Ros\u00e9e","year":"2016","journal-title":"Blood."},{"issue":"13","key":"10.1016\/j.cytogfr.2021.03.006_bib0600","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood-2015-12-684399","article-title":"Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis","volume":"127","author":"Das","year":"2016","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.cytogfr.2021.03.006_bib0605","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2016-02-700013","article-title":"Therapeutic effect of JAK1\/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice","volume":"128","author":"Maschalidi","year":"2016","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.cytogfr.2021.03.006_bib0610","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1182\/blood.2019001333","article-title":"Calming the storm in HLH","volume":"134","author":"Zinter","year":"2019","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.cytogfr.2021.03.006_bib0615","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1182\/blood.2019000761","article-title":"Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis","volume":"134","author":"Albeituni","year":"2019","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.cytogfr.2021.03.006_bib0620","doi-asserted-by":"crossref","first-page":"E47","DOI":"10.1002\/ajh.24971","article-title":"Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: a single patient experience","volume":"93","author":"Slostad","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"5","key":"10.1016\/j.cytogfr.2021.03.006_bib0625","doi-asserted-by":"crossref","first-page":"E123","DOI":"10.1002\/ajh.25063","article-title":"Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: a second experience","volume":"93","author":"Zandvakili","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"23","key":"10.1016\/j.cytogfr.2021.03.006_bib0630","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1182\/bloodadvances.2019000898","article-title":"Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1\/2 inhibitor ruxolitinib","volume":"3","author":"Goldsmith","year":"2019","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.cytogfr.2021.03.006_bib0635","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.hemonc.2017.07.002","article-title":"Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: first case report","volume":"12","author":"Sin","year":"2019","journal-title":"Hematol. Stem Cell Ther."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0640","article-title":"Ruxolitinib for the treatment of lymphoma-associated hemophagocytic lymphohistiocytosis: a cautionary tale [published online ahead of print, 2019 Oct 1]","author":"Trantham","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"December (12)","key":"10.1016\/j.cytogfr.2021.03.006_bib0645","doi-asserted-by":"crossref","first-page":"e630","DOI":"10.1016\/S2352-3026(19)30156-5","article-title":"Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial","volume":"6","author":"Ahmed","year":"2019","journal-title":"Lancet Haematol."},{"issue":"23","key":"10.1016\/j.cytogfr.2021.03.006_bib0650","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood.2018894618","article-title":"Recommendations for the management of hemophagocytic lymphohistiocytosis in adults","volume":"133","author":"La Ros\u00e9e","year":"2019","journal-title":"Blood."},{"issue":"10223","key":"10.1016\/j.cytogfr.2021.03.006_bib0655","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(20)30317-2","article-title":"Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury","volume":"395","author":"Russell","year":"2020","journal-title":"Lancet."},{"issue":"10225","key":"10.1016\/j.cytogfr.2021.03.006_bib0660","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0140-6736(20)30361-5","article-title":"On the use of corticosteroids for 2019-nCoV pneumonia","volume":"395","author":"Shang","year":"2020","journal-title":"Lancet."},{"issue":"December","key":"10.1016\/j.cytogfr.2021.03.006_bib0665","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19","volume":"11","author":"Kalil","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.cytogfr.2021.03.006_bib0670","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrd.2017.267","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"17","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0675","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41409-019-0731-x","article-title":"Ruxolitinib in refractory acute and chronic graft-versus-host disease:a multicenter survey study","volume":"55","author":"Gomez","year":"2020","journal-title":"Bone Marrow Trans."},{"issue":"6515","key":"10.1016\/j.cytogfr.2021.03.006_bib0680","doi-asserted-by":"crossref","first-page":"eabd4585","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFN in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0685","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1001\/jama.290.24.3222","article-title":"Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome","volume":"290","author":"Loutfy","year":"2003","journal-title":"JAMA."},{"issue":"May (8)","key":"10.1016\/j.cytogfr.2021.03.006_bib0690","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3389\/fpubh.2020.00185","article-title":"Therapeutic options for coronavirus disease 2019 (COVID-19) - modulation of Type I interferon response as a promising strategy?","volume":"15","author":"Mary","year":"2020","journal-title":"Front. Public Health"},{"issue":"November (11)","key":"10.1016\/j.cytogfr.2021.03.006_bib0695","article-title":"Rationale for COVID-19 treatment by nebulized Interferon-\u03b2-1b-Literature review and personal preliminary experience","volume":"30","author":"Mary","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0700","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa410","article-title":"Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19","author":"Chu","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"August (8)","key":"10.1016\/j.cytogfr.2021.03.006_bib0705","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S2213-2600(20)30225-3","article-title":"Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy","volume":"8","author":"George","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"5","key":"10.1016\/j.cytogfr.2021.03.006_bib0710","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","article-title":"Imbalanced host response to SARS-CoV-2 drives development of COVID-19","volume":"181","author":"Blanco-Melo","year":"2020","journal-title":"Cell."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0715","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jaci.2020.04.029","article-title":"Type I IFN immunoprofiling in COVID-19 patients","volume":"146","author":"Trouillet-Assant","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6504","key":"10.1016\/j.cytogfr.2021.03.006_bib0720","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1126\/science.abc6027","article-title":"Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients","volume":"369","author":"Hadjadj","year":"2020","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.cytogfr.2021.03.006_bib0725","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.chom.2020.05.009","article-title":"The innate immune system: fighting on the front lines or fanning the flames of COVID-19?","volume":"27","author":"McKechnie","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"June (6)","key":"10.1016\/j.cytogfr.2021.03.006_bib0730","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.chom.2020.05.008","article-title":"Type I and Type III interferons - induction, signaling, evasion, and application to combat COVID-19","volume":"27","author":"Park","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0735","article-title":"Genetic mechanisms of critical illness in Covid-19","author":"Pairo-Castineira","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0740","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1073\/pnas.1220098110","article-title":"STAT2 deficiency and susceptibility to viral illness in humans","volume":"110","author":"Hambleton","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0745","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac4227","article-title":"Human ifnar2 deficiency: lessons for antiviral immunity","volume":"7","author":"Duncan","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"October (6515)","key":"10.1016\/j.cytogfr.2021.03.006_bib0750","article-title":"Inborn errors of type I IFN immunity in patients with life-threatening COVID-19","volume":"23","author":"Zhang","year":"2020","journal-title":"Science."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0755","article-title":"Survival factors and metabolic pathogenesis in elderly patients (\u226565) with COVID-19: a multicenter study of 223 cases Res","author":"Mei","year":"2020","journal-title":"Square"},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0760","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF00320399","article-title":"Age-related decline of human interferon alpha and interferon gamma production","volume":"48","author":"Abb","year":"1984","journal-title":"Blut"},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0765","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.nut.2012.04.019","article-title":"Decreased interferon-\u03b1 and interferon-\u03b2 production in obesity and expression of suppressor of cytokine signaling","volume":"29","author":"Teran-Cabanillas","year":"2013","journal-title":"Nutrition"},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0770","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/clinchem\/hvaa089","article-title":"Type I interferon in children with viral or bacterial infections","volume":"66","author":"Trouillet-Assant","year":"2020","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0775","first-page":"4259","article-title":"Oxidative stress and thrombosis during aging: the roles of oxidative stress in RBSs in venous thrombosis","author":"Wang","year":"2002","journal-title":"Int. J. Mol. Sci."},{"issue":"Supplement 1","key":"10.1016\/j.cytogfr.2021.03.006_bib0780","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/blood-2018-99-112109","article-title":"Interferon-alpha2 significantly downregulates upregulated oxidative stress genes and upregulates downregulated anti-oxidative defence genes in patients with polycythemia vera and associated neoplasms","volume":"132","author":"Skov","year":"2018","journal-title":"Blood."},{"issue":"October (5)","key":"10.1016\/j.cytogfr.2021.03.006_bib0785","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1186\/ar4326","article-title":"Interferon alpha inhibits antigen-specific production of proinflammatory cytokines and enhances antigen-specific transforming growth factor beta production in antigen-induced arthritis","volume":"15","author":"Chalise","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0790","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.cyto.2012.12.005","article-title":"Inhibition of the type I immune responses of human monocytes by IFN-alpha and IFN-beta","volume":"61","author":"de Paus","year":"2013","journal-title":"Cytokine"},{"issue":"July (13)","key":"10.1016\/j.cytogfr.2021.03.006_bib0795","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.2147\/IDR.S258639","article-title":"Role of Monocytes\/Macrophages in Covid-19 pathogenesis: implications for therapy","volume":"22","author":"G\u00f3mez-Rial","year":"2020","journal-title":"Infect. Drug Resist."},{"issue":"September (11)","key":"10.1016\/j.cytogfr.2021.03.006_bib0800","article-title":"Increased serum levels of sCD14 and sCD163 indicate a preponderant role for monocytes in COVID-19 immunopathology","volume":"23","author":"G\u00f3mez-Rial","year":"2020","journal-title":"Front. Immunol."},{"issue":"September","key":"10.1016\/j.cytogfr.2021.03.006_bib0805","article-title":"Monocyte activation in systemic Covid-19 infection: assay and rationale","volume":"59","author":"Martinez","year":"2020","journal-title":"EBioMedicine."},{"issue":"September (257)","key":"10.1016\/j.cytogfr.2021.03.006_bib0810","article-title":"Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: lessons from SARS and MERS, and potential therapeutic interventions","volume":"15","author":"Jafarzadeh","year":"2020","journal-title":"Life Sci."},{"issue":"June (6)","key":"10.1016\/j.cytogfr.2021.03.006_bib0815","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41577-020-0331-4","article-title":"Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages","volume":"20","author":"Merad","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0820","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1182\/blood-2011-03-340992","article-title":"Increase in circulating CD4(+)CD25(+)Foxp3(+) T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-alpha","volume":"118","author":"Riley","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0825","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1084\/jem.20030152","article-title":"Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3","volume":"198","author":"Chen","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0830","doi-asserted-by":"crossref","first-page":"99","DOI":"10.4049\/jimmunol.174.1.99","article-title":"Type I IFN negatively regulates CD8+ t cell responses through IL-10-producing CD4+ t regulatory 1 cells","volume":"174","author":"Dikopoulos","year":"2005","journal-title":"J. Immunol."},{"issue":"April (4)","key":"10.1016\/j.cytogfr.2021.03.006_bib0835","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1084\/jem.20160880","article-title":"Inflammatory monocytes require type I interferon receptor signaling to activate NK cells via IL-18 during a mucosal viral infection","volume":"214","author":"Lee","year":"2017","journal-title":"J. Exp. Med."},{"issue":"November","key":"10.1016\/j.cytogfr.2021.03.006_bib0840","first-page":"1","article-title":"Dendritic cells in COVID-19 immunopathogenesis: insights for a possible role in determining disease outcome","volume":"16","author":"Borges","year":"2020","journal-title":"Int. Rev. Immunol."},{"issue":"January (1)","key":"10.1016\/j.cytogfr.2021.03.006_bib0845","article-title":"Direct type I IFN but not MDA5\/TLR3 activation of dendritic cells is required for maturation and metabolic shift to glycolysis after poly IC stimulation","volume":"12","author":"Pantel","year":"2014","journal-title":"PLoS Biol."},{"issue":"2","key":"10.1016\/j.cytogfr.2021.03.006_bib0850","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/onc.2011.221","article-title":"Inflammatory signaling compromises cell responses to interferon","volume":"31","author":"Wei-Chun","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0855","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/107327480801500302","article-title":"Activated STAT-3 in melanoma","volume":"15","author":"Messina","year":"2008","journal-title":"Cancer Control"},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0860","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jhep.2006.01.037","article-title":"Oxidative stress inhibits IFN-alpha2-induced antiviral gene expression by blocking the JAK-STAT pathway","volume":"45","author":"Bona","year":"2006","journal-title":"J. Hepatol."},{"issue":"December","key":"10.1016\/j.cytogfr.2021.03.006_bib0865","first-page":"26","article-title":"Ruxolitinib and interferon-\u03b12 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study","author":"S\u00f8rensen","year":"2019","journal-title":"Haematologica."},{"issue":"5","key":"10.1016\/j.cytogfr.2021.03.006_bib0870","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1159\/000495897","article-title":"Type I interferons: distinct biological activities and current applications for viral infection","volume":"51","author":"Li","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"issue":"October","key":"10.1016\/j.cytogfr.2021.03.006_bib0875","first-page":"1","article-title":"COVID-19 and myeloproliferative neoplasms: some considerations","volume":"26","author":"Kamaz","year":"2020","journal-title":"Leukemia."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0880","series-title":"COVID-19 Treatment Guidelines","author":"NIH","year":"2020"},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0885","article-title":"COVID-19 and myeloid malignancies: managing patients during the pandemic","author":"Harrison","year":"2020","journal-title":"Presented at: Virtual 25th EHA Congress"},{"issue":"10","key":"10.1016\/j.cytogfr.2021.03.006_bib0890","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1038\/s41375-020-01032-0","article-title":"COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey","volume":"34","author":"Breccia","year":"2020","journal-title":"Leukemia."},{"issue":"January","key":"10.1016\/j.cytogfr.2021.03.006_bib0895","first-page":"1","article-title":"High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib","volume":"7","author":"Barbui","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0900","series-title":"Response to Pegylated Interferon in a COVID-19 Positive Elderly Woman with Primary Myelofibrosis Treated with Ruxolitinib","author":"Frankel","year":"2021"},{"issue":"October (10)","key":"10.1016\/j.cytogfr.2021.03.006_bib0905","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S1473-3099(20)30701-5","article-title":"Long-term consequences of COVID-19: research needs","volume":"20","author":"Yelin","year":"2020","journal-title":"Lancet Infect. Dis."},{"issue":"January","key":"10.1016\/j.cytogfr.2021.03.006_bib0910","first-page":"1","article-title":"Statins as an adjunctive therapy for COVID-19: the biological and clinical plausibility","volume":"6","author":"Kashour","year":"2021","journal-title":"Immunopharmacol. Immunotoxicol."},{"issue":"November (21","key":"10.1016\/j.cytogfr.2021.03.006_bib0915","doi-asserted-by":"crossref","first-page":"4873","DOI":"10.1111\/bph.15166","article-title":"Statins: could an old friend help in the fight against COVID-19?","volume":"177","author":"Rodrigues-Diez","year":"2020","journal-title":"Br. J. Pharmacol."},{"issue":"March (3)","key":"10.1016\/j.cytogfr.2021.03.006_bib0920","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1586\/era.11.10","article-title":"Hydroxycarbamide: a user\u2019s guide for chronic myeloproliferative disorders","volume":"11","author":"Spivak","year":"2011","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0925","doi-asserted-by":"crossref","DOI":"10.1177\/1076029619895111","article-title":"Effect of hydroxyurea treatment on the inflammatory markers among children with sickle cell disease","volume":"26","author":"Zahran","year":"2020","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0930","doi-asserted-by":"crossref","first-page":"14829","DOI":"10.1038\/s41598-019-51339-x","article-title":"Hydroxyurea alters circulating monocyte subsets and dampens its inflammatory potential in sickle cell anemia patients","volume":"9","author":"Guarda","year":"2019","journal-title":"Sci. Rep."},{"issue":"Suppl 3","key":"10.1016\/j.cytogfr.2021.03.006_bib0935","first-page":"101","article-title":"Hydroxyurea: overview of clinical data and antiretroviral and immunomodulatory effects","volume":"4","author":"Lori","year":"1999","journal-title":"Antivir Ther."},{"issue":"9","key":"10.1016\/j.cytogfr.2021.03.006_bib0940","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2165\/00002018-200326090-00002","article-title":"Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns","volume":"26","author":"Lisziewicz","year":"2003","journal-title":"Drug Saf."},{"issue":"November (1)","key":"10.1016\/j.cytogfr.2021.03.006_bib0945","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s40249-020-00780-6","article-title":"Increased circulating level of interleukin-6 and CD8+ T cell exhaustion are associated with progression of COVID-19","volume":"9","author":"Yang","year":"2020","journal-title":"Infect. Dis. Poverty"},{"issue":"August (1)","key":"10.1016\/j.cytogfr.2021.03.006_bib0950","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s40249-020-00723-1","article-title":"Abnormal immunity of non-survivors with COVID-19: predictors for mortality","volume":"9","author":"Zhao","year":"2020","journal-title":"Infect. Dis. Poverty"},{"issue":"August (5)","key":"10.1016\/j.cytogfr.2021.03.006_bib0955","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood.2019001113","article-title":"Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population","volume":"134","author":"Cordua","year":"2019","journal-title":"Blood."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib0960","article-title":"Gout, rheumatoid arthritis and the risk of death from COVID-19: an analysis of the UK Biobank","author":"Merriman","year":"2020","journal-title":"medRxiv"},{"issue":"July (7)","key":"10.1016\/j.cytogfr.2021.03.006_bib0965","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1136\/gutjnl-2020-321269","article-title":"COVID-19 and immunomodulation in IBD","volume":"69","author":"Neurath","year":"2020","journal-title":"Gut"},{"issue":"July (1)","key":"10.1016\/j.cytogfr.2021.03.006_bib0970","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1161\/CIRCULATIONAHA.120.047549","article-title":"The science underlying COVID-19: implications for the cardiovascular system","volume":"142","author":"Liu","year":"2020","journal-title":"Circulation"},{"issue":"January (1)","key":"10.1016\/j.cytogfr.2021.03.006_bib0975","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/ejh.13519","article-title":"SARS-CoV-2 infection among patients with haematological disorders: severity and one-month outcome in 66 Danish patients in a nationwide cohort study","volume":"106","author":"Glenth\u00f8j","year":"2021","journal-title":"Eur. J. Haematol."},{"issue":"December (1)","key":"10.1016\/j.cytogfr.2021.03.006_bib0980","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13027-020-00339-y","article-title":"Clinical characteristics, outcomes, and risk factors for mortality in hospitalized patients with COVID-19 and cancer history: a propensity score-matched study","volume":"15","author":"Sorouri","year":"2020","journal-title":"Infect Agent Cancer."},{"issue":"July (1)","key":"10.1016\/j.cytogfr.2021.03.006_bib0985","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1038\/s41467-020-17703-6","article-title":"Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion","volume":"11","author":"Simon","year":"2020","journal-title":"Nat. Commun."},{"issue":"July (13)","key":"10.1016\/j.cytogfr.2021.03.006_bib0990","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.2147\/IDR.S258639","article-title":"Role of Monocytes\/Macrophages in Covid-19 pathogenesis: implications for therapy","volume":"22","author":"G\u00f3mez-Rial","year":"2020","journal-title":"Infect. Drug Resist."},{"issue":"December (6)","key":"10.1016\/j.cytogfr.2021.03.006_bib0995","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/82763","article-title":"IL-6 switches the differentiation of monocytes from dendritic cells to macrophages","volume":"1","author":"Chomarat","year":"2000","journal-title":"Nat. Immunol."},{"issue":"7","key":"10.1016\/j.cytogfr.2021.03.006_bib1000","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133494","article-title":"Obesity is a positive modulator of IL-6R and IL-6 expression in the subcutaneous adipose tissue: significance for metabolic inflammation","volume":"10","author":"Sindhu","year":"2015","journal-title":"PLoS One"},{"issue":"February (21)","key":"10.1016\/j.cytogfr.2021.03.006_bib1005","article-title":"Loss-of-function polymorphism in IL6R reduces risk of JAK2V617F somatic mutation and myeloproliferative neoplasm: a Mendelian randomization study","volume":"19","author":"Pedersen","year":"2020","journal-title":"EClinicalMedicine."},{"issue":"10224","key":"10.1016\/j.cytogfr.2021.03.006_bib1010","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet."},{"issue":"3","key":"10.1016\/j.cytogfr.2021.03.006_bib1015","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/path.5471","article-title":"Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19)","volume":"251","author":"Bourgonje","year":"2020","journal-title":"J. Pathol."},{"issue":"September (5)","key":"10.1016\/j.cytogfr.2021.03.006_bib1020","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/0004563220928361","article-title":"Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: a closer look at angiotensin-converting enzyme 2 (ACE2)","volume":"57","author":"Zemlin","year":"2020","journal-title":"Ann. Clin. Biochem."},{"issue":"October (4)","key":"10.1016\/j.cytogfr.2021.03.006_bib1025","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/joim.13101","article-title":"COVID-19 and renin-angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) - is there any scientific evidence for controversy?","volume":"288","author":"Aleksova","year":"2020","journal-title":"J Intern Med."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib1030","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.cell.2020.04.035","article-title":"SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues","volume":"181","author":"Ziegler","year":"2020","journal-title":"Cell"},{"issue":"September (5)","key":"10.1016\/j.cytogfr.2021.03.006_bib1035","first-page":"e01928","article-title":"Antiviral activity of type I, II, and III interferons counterbalances ACE2 inducibility and restricts SARS-CoV-2","volume":"11","author":"Busnadiego","year":"2020","journal-title":"mBio."},{"issue":"September(9)","key":"10.1016\/j.cytogfr.2021.03.006_bib1040","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41577-020-00416-8","article-title":"ACE2 is not induced by interferon","volume":"20","author":"Saffern","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib1045","article-title":"Interferons and viruses induce a novel primate-specific isoform dACE2 and not the SARS-CoV-2 receptor ACE2","author":"Onabajo","year":"2020","journal-title":"bioRxiv"},{"issue":"1","key":"10.1016\/j.cytogfr.2021.03.006_bib1050","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/cei.12612","article-title":"Human monocyte subsets exhibit divergent angiotensin I-converting activity","volume":"181","author":"Rutkowska-Zapala","year":"2015","journal-title":"Clin. Exp. Immunol."},{"issue":"10","key":"10.1016\/j.cytogfr.2021.03.006_bib1055","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1161\/ATVBAHA.108.180513","article-title":"Monocytes in acute coronary syndromes","volume":"29","author":"Shantsila","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"June (1)","key":"10.1016\/j.cytogfr.2021.03.006_bib1060","article-title":"The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis","volume":"9","author":"Barone","year":"2020","journal-title":"Oncoimmunology."},{"issue":"September","key":"10.1016\/j.cytogfr.2021.03.006_bib1065","article-title":"Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment","volume":"218","author":"Yeleswaram","year":"2020","journal-title":"Clin. Immunol."},{"issue":"May","key":"10.1016\/j.cytogfr.2021.03.006_bib1070","article-title":"Activation of the SARS-CoV-2 receptor Ace2 by cytokines through pan JAK-STAT enhancers","volume":"11","author":"Hennighausen","year":"2020","journal-title":"bioRxiv [Preprint]."},{"issue":"December","key":"10.1016\/j.cytogfr.2021.03.006_bib1075","article-title":"Activation of interferon-stimulated transcriptomes and ACE2 isoforms in human airway epithelium is curbed by Janus kinase inhibitors","volume":"11","author":"Lee","year":"2020","journal-title":"Res Sq [Preprint]."},{"issue":"11","key":"10.1016\/j.cytogfr.2021.03.006_bib1080","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3324\/haematol.2011.055392","article-title":"The JAK2 46\/1 haplotype: a marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasm, and impaired defence against infection?","volume":"96","author":"Hermouet","year":"2011","journal-title":"Haematologica."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib1085","series-title":"Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Hematopoietic Stem Cells in JAK2-Mutant Myeloproliferative Neoplasms","author":"Van Egeren","year":"2020"},{"key":"10.1016\/j.cytogfr.2021.03.006_bib1090","series-title":"LBA-1 Driver Mutation Acquisition in Utero and Childhood Followed By Lifelong Clonal Evolution Underlie Myeloproliferative Neoplasms","author":"Williams","year":"2020"},{"key":"10.1016\/j.cytogfr.2021.03.006_bib1095","article-title":"Double-blind, placebo-controlled multi-center study to assess the efficacy and safety of ruxolitinib in patients with COVID-19 associated cytokine storm (RUXCOVID).\u201d","author":"A Phase 3 Randomized","year":"2020","journal-title":"ClinicalTrials.gov."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib1100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1099\/vir.0.83391-0","article-title":"Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures","volume":"89","author":"Randall","year":"2008","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.cytogfr.2021.03.006_bib1105","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.cytogfr.2020.07.010","article-title":"Are we fully exploiting type I Interferons in today\u2019s fight against COVID-19 pandemic?","volume":"54","author":"Aric\u00f2","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"issue":"July (49)","key":"10.1016\/j.cytogfr.2021.03.006_bib1110","article-title":"Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19","volume":"5","author":"Lee","year":"2020","journal-title":"Sci. Immunol."},{"issue":"July (1)","key":"10.1016\/j.cytogfr.2021.03.006_bib1115","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1038\/s41467-020-17665-9","article-title":"Activation and evasion of type I interferon responses by SARS-CoV-2","volume":"11","author":"Lei","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.cytogfr.2021.03.006_bib1120","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-020-00306-4","article-title":"Type I IFN deficiency: an immunological characteristic of severe COVID-19 patients","volume":"5","author":"Wang","year":"2020","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["Cytokine &amp; Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610121000332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610121000332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T11:00:44Z","timestamp":1761217244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610121000332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":225,"alternative-id":["S1359610121000332"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2021.03.006","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1\/2 inhibitors in combination with interferon","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2021.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}